middle.news
Nexalis Therapeutics Links Director Fees to Phase 2 Trial Milestones with Share Rights
3:06pm on Tuesday 14th of July, 2026 AEST
•
Healthcare
Read Story
Nexalis Therapeutics Links Director Fees to Phase 2 Trial Milestones with Share Rights
3:06pm on Tuesday 14th of July, 2026 AEST
Key Points
Share rights issued to directors instead of cash fees
Vesting depends on success of Phase 2 clinical trials
Board applied a higher deemed issue price than formula
Capital preserved for clinical programs and corporate costs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE